Synlogic, Inc. (SYBX): Price and Financial Metrics

Synlogic, Inc. (SYBX): $1.60

0.04 (+2.56%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add SYBX to Watchlist
Sign Up

SYBX Price/Volume Stats

Current price $1.60 52-week high $8.85
Prev. close $1.56 52-week low $1.35
Day low $1.60 Volume 2,301
Day high $1.65 Avg. volume 75,901
50-day MA $1.60 Dividend yield N/A
200-day MA $2.24 Market Cap 18.73M

SYBX Stock Price Chart Interactive Chart >


Synlogic, Inc. (SYBX) Company Bio


Synlogic, Inc., a biopharmaceutical company, offers synthetic biotics that perform specific metabolic functions from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. It provides SYNB1010 for urea cycle disorder, a synthetic biotic that is designed to remove excess ammonia from the blood; and SYNB2010 for phenylketonuria, a synthetic biotic that is designed to remove excess phenylalanine from the blood. The company was founded in 2013 and is based in Cambridge, Massachusetts.


SYBX Latest News Stream


Event/Time News Detail
Loading, please wait...

SYBX Latest Social Stream


Loading social stream, please wait...

View Full SYBX Social Stream

Latest SYBX News From Around the Web

Below are the latest news stories about SYNLOGIC INC that investors may wish to consider to help them evaluate SYBX as an investment opportunity.

Synlogic Announces Contract with the Air Force Research Lab

- Selection of Synlogic reflects Company’s leadership in process development and manufacturing of therapeutics based on synthetic biology -CAMBRIDGE, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that it has entered into an approximately $1 million subcontract under an Air Force Research Lab (AFRL) prime contract to

Yahoo | December 27, 2023

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, announced that an abstract outlining the SYNB1353 program as a potential treatment for homocystinuria (HCU), includin

Yahoo | December 7, 2023

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

NEW YORK, NY / ACCESSWIRE / November 14, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November ...

Yahoo | November 14, 2023

Synlogic Inc (SYBX) Reports Q3 2023 Financial Results with Extended Cash Runway and Clinical ...

Key Developments and Financial Highlights for Investors

Yahoo | November 9, 2023

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

- Underwritten public offering of $21.0 million and earned $2.5 million milestone payment from Roche have extended cash runway into the first half of 2025 - - Progress of the Synpheny-3 pivotal trial in phenylketonuria (PKU) supports enrollment completion in 2024, with top-line data in the first half of 2025 - - Company received Fast Track Designation from the FDA for labafenogene marselecobac (SYNB1934) as a potential treatment for PKU - CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Synlo

Yahoo | November 9, 2023

Read More 'SYBX' Stories Here

SYBX Price Returns

1-mo 0.63%
3-mo -12.57%
6-mo -49.84%
1-year -78.71%
3-year -96.76%
5-year -98.49%
YTD -58.44%
2023 -66.23%
2022 -68.60%
2021 12.04%
2020 -16.28%
2019 -63.20%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!